$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000147929016000049 Filed on August 05, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$75.00K	$75.00K
YoY Change	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.018M	$6.360M
YoY Change	10.35%	30.95%
% of Gross Profit
Research & Development	$2.000M	$10.30M
YoY Change	-80.59%	27.04%
% of Gross Profit
Depreciation & Amortization	$360.0K	$550.0K
YoY Change	-34.55%	10.0%
% of Gross Profit
Operating Expenses	$24.16M	$16.66M
YoY Change	44.99%	28.5%
Operating Profit	-$24.08M	-$16.59M
YoY Change	45.19%	28.67%
Interest Expense	$286.0K	$279.0K
YoY Change	2.51%	4.49%
% of Operating Profit
Other Income/Expense, Net	-$143.0K	-$76.00K
YoY Change	88.16%	11.76%
Pretax Income	-$24.60M	-$16.81M
YoY Change	46.34%	26.39%
Income Tax
% Of Pretax Income
Net Earnings	-$24.60M	-$16.81M
YoY Change	46.4%	26.33%
Net Earnings / Revenue	-32802.67%	-22406.67%
Basic Earnings Per Share	-$0.88	-$0.71
Diluted Earnings Per Share	-$0.88	-$0.71
COMMON SHARES
Basic Shares Outstanding	28.09M shares	23.58M shares
Diluted Shares Outstanding	28.09M shares	23.58M shares

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$216.9M	$135.3M
YoY Change	60.31%	-33.45%
Cash & Equivalents	$52.65M	$96.42M
Short-Term Investments	$164.3M	$38.90M
Other Short-Term Assets	$1.600M	$1.900M
YoY Change	-15.79%	1317.91%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$218.6M	$137.3M
YoY Change	59.23%	-33.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.66M	$19.13M
YoY Change	-7.71%	17.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$14.10M
YoY Change	-100.0%
Other Assets	$214.0K	$374.0K
YoY Change	-42.78%
Total Long-Term Assets	$18.45M	$33.96M
YoY Change	-45.67%	102.64%
TOTAL ASSETS
Total Short-Term Assets	$218.6M	$137.3M
Total Long-Term Assets	$18.45M	$33.96M
Total Assets	$237.0M	$171.2M
YoY Change	38.43%	-23.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.982M	$2.211M
YoY Change	34.87%	-17.71%
Accrued Expenses	$5.622M	$5.040M
YoY Change	11.55%	0.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.300M	$2.900M
YoY Change	13.79%	-73.64%
Total Short-Term Liabilities	$11.92M	$10.16M
YoY Change	17.34%	-45.87%
LONG-TERM LIABILITIES
Long-Term Debt	$3.700M	$7.000M
YoY Change	-47.14%	900.0%
Other Long-Term Liabilities	$100.0K	$5.200M
YoY Change	-98.08%	-1.89%
Total Long-Term Liabilities	$100.0K	$12.20M
YoY Change	-99.18%	103.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.92M	$10.16M
Total Long-Term Liabilities	$100.0K	$12.20M
Total Liabilities	$21.23M	$22.38M
YoY Change	-5.1%	-9.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$376.8M	-$291.0M
YoY Change	29.47%	26.19%
Common Stock	$592.4M	$439.9M
YoY Change	34.68%	2.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$215.8M	$148.8M
YoY Change
Total Liabilities & Shareholders Equity	$237.0M	$171.2M
YoY Change	38.43%	-23.33%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$24.60M	-$16.81M
YoY Change	46.4%	26.33%
Depreciation, Depletion And Amortization	$360.0K	$550.0K
YoY Change	-34.55%	10.0%
Cash From Operating Activities	-$16.33M	-$12.48M
YoY Change	30.85%	2.72%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$490.0K
YoY Change	-38.78%	-79.84%
Acquisitions
YoY Change
Other Investing Activities	$29.34M	-$53.08M
YoY Change	-155.28%
Cash From Investing Activities	$29.04M	-$53.56M
YoY Change	-154.22%	2104.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-710.0K	8.750M
YoY Change	-108.11%	-93.27%
NET CHANGE
Cash From Operating Activities	-16.33M	-12.48M
Cash From Investing Activities	29.04M	-53.56M
Cash From Financing Activities	-710.0K	8.750M
Net Change In Cash	12.00M	-57.29M
YoY Change	-120.95%	-149.62%
FREE CASH FLOW
Cash From Operating Activities	-$16.33M	-$12.48M
Capital Expenditures	-$300.0K	-$490.0K
Free Cash Flow	-$16.03M	-$11.99M
YoY Change	33.69%	23.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2015Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	5346000	USD
	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2015Q4	rvnc	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	1751000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28484935	shares
CY2016Q2	rvnc	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	0	USD
CY2016Q2	rvnc	Cash Cash Equivalentsand Investments CashCashEquivalentsandInvestments	216900000	USD
CY2016Q2	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	3659000	USD
CY2015Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	3135000	USD
CY2016Q2	rvnc	Financing Obligation Current FinancingObligationCurrent	3314000	USD
CY2016Q2	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	6994000	USD
CY2016Q2	rvnc	Financing Obligation Future Minimum Payments Duein Three Years FinancingObligationFutureMinimumPaymentsDueinThreeYears	949000	USD
CY2016Q2	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	3936000	USD
CY2016Q2	rvnc	Financing Obligation Future Minimum Payments Next Twelve Months FinancingObligationFutureMinimumPaymentsNextTwelveMonths	2109000	USD
CY2015Q2	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	89000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	47000	USD
CY2016Q2	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-413000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-428000	USD
CY2015Q2	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	0	USD
	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	39000	USD
CY2016Q2	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	0	USD
	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	0	USD
CY2015Q2	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	0	USD
	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	5000	USD
CY2016Q2	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	0	USD
	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	0	USD
CY2015Q2	rvnc	Noncash Interest Expense NoncashInterestExpense	89000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	144000	USD
CY2016Q2	rvnc	Noncash Interest Expense NoncashInterestExpense	105000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	217000	USD
CY2016Q2	rvnc	Working Capital Surplus WorkingCapitalSurplus	206600000	USD
	rvnc	Writeoffof Fixed Assets WriteoffofFixedAssets	28000	USD
	rvnc	Writeoffof Fixed Assets WriteoffofFixedAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	412000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	74000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	145000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	300000	USD
	us-gaap	Interest Paid InterestPaid	384000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2657000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2982000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-128000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-786000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6245000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5622000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-40000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	148000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	585537000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	592362000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2407000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4724000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3252000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6229000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	39000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2015Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2016Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1949000	USD
CY2016Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1900000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1949000	USD
CY2015Q4	us-gaap	Assets Assets	275822000	USD
CY2016Q2	us-gaap	Assets Assets	237009000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	253963000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	218557000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	198186000	USD
CY2016Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	207375000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	149000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	40000	USD
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	198226000	USD
CY2016Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	207227000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	50688000	USD
CY2016Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	164293000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52439000	USD
CY2016Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	164293000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171032000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96417000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201615000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52651000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-74615000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-148964000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	32000	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1414000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28288464	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28481172	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28288464	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28481172	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16817000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32219000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24640000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44302000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3773000	USD
CY2016Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3714000	USD
	us-gaap	Depreciation Depreciation	1075000	USD
	us-gaap	Depreciation Depreciation	699000	USD
CY2016Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1842000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
CY2016Q2	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	200000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	200000	USD
CY2015Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	89000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	100000	USD
CY2016Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	105000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	217000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-938000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	279000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2337000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-33000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	345000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	587000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	286000	USD
	us-gaap	Interest Expense InterestExpense	601000	USD
CY2015Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	190000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	279000	USD
	us-gaap	Interest Expense InterestExpense	444000	USD
CY2016Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	181000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	384000	USD
	us-gaap	Interest Paid InterestPaid	300000	USD
CY2015Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	49000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	76000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	938000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5578000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5394000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	26591000	USD
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2600000	USD
CY2016Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2600000	USD
	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	324000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	635000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2015Q4	us-gaap	Liabilities Liabilities	22570000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	21233000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275822000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	237009000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12037000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11918000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	1751000	USD
CY2016Q2	us-gaap	Long Term Investments LongTermInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6190000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1310000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55293000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-115644000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25512000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32010000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32000000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-16805000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-32207000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-24602000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-24600000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44500000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44490000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16805000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32207000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24602000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44490000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16805000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-32207000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24602000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-44490000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	20000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	90000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	16663000	USD
	us-gaap	Operating Expenses OperatingExpenses	31913000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	24159000	USD
	us-gaap	Operating Expenses OperatingExpenses	43978000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16588000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-31763000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-24084000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43828000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	45940000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2614000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5763000	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	214000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-38000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	188000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-76000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-123000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-143000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-268000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	182000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	620000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	341000	USD
CY2016Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	53076000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	159755000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2292000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	994000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1625000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1613000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	46050000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1000000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19708000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17658000	USD
CY2016Q2	us-gaap	Purchase Obligation PurchaseObligation	19700000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	956000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1725000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2652000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10303000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19557000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15192000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27556000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2000000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	35000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-332273000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-376762000	USD
CY2015Q2	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	150000	USD
CY2016Q2	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	150000	USD
	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	9831000	USD
	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	0	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6360000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12356000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7018000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14473000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4724000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6229000	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	50688000	USD
CY2016Q2	us-gaap	Short Term Investments ShortTermInvestments	164293000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	253252000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	215776000	USD
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2016Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2015Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2016Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2016Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2015Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2016Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23584910	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28047671	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23584910	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23560133	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28089731	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28047671	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23560133	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28089731	shares
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation, or Medicis, entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational, injectable botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT002 injectable and RT001 topical from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> in 2014, and (iii) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT002 injectable or RT001 topical by the Company, or Product Approval Payment. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The proceeds sharing arrangement payment derivative in (ii) above was settled upon completion of our IPO. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.75</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">0.82%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">11.00%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2020. The Company did not make any payments under the Product Approval Payment during </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of Condensed Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include accruals, stock-based compensation, the fair value of derivative liability associated with the Medicis settlement, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001479290-16-000049-index-headers.html	Edgar Link	pending
0001479290-16-000049-index.html	Edgar Link	pending
0001479290-16-000049.txt	Edgar Link	pending
0001479290-16-000049-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20160630.xml	Edgar Link	completed
rvnc-20160630.xsd	Edgar Link	pending
rvnc-20160630_cal.xml	Edgar Link	unprocessable
rvnc-20160630_def.xml	Edgar Link	unprocessable
rvnc-20160630_lab.xml	Edgar Link	unprocessable
rvnc-20160630_pre.xml	Edgar Link	unprocessable
rvnc-q216exhibit311.htm	Edgar Link	pending
rvnc-q216exhibit312.htm	Edgar Link	pending
rvnc-q216exhibit321.htm	Edgar Link	pending
rvnc-q216exhibit322.htm	Edgar Link	pending
rvncq21610q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2016 Q2 Form 10-Q Financial Statement

#000147929016000049 Filed on August 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2016 Q2 Form 10-Q Financial Statement

#000147929016000049 Filed on August 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc